Trial · NCT07188740
Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia
NCT07188740, Phase 1, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia. Trials, record NCT07188740. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07188740
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia
- NCT number
- NCT07188740
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 32 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- DNMT3A Gene Mutation
- Interventions
- Metformin
- First posted
- 2025-09-23
- Last updated
- 2026-08-10
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of major molecular response based on the variant-allele frequency (VAF) of DNMT3A R882 mutation at 6-month follow-up | up to 6 months | An effective decline in VAF is defined as an absolute reduction of ≥10% when the baseline variant-allele frequency is greater than 20%; a relative reduction of ≥50% when the baseline variant-allele frequency is ≤20%. Variant-allele frequency is tested in bone-marrow samples via next-generation sequencing (NGS). |
| Secondary | Rate of major molecular response based on the variant-allele frequency (VAF) of DNMT3A R882 mutation at 3-month follow-up | up to 3 months | The judgment standard for major molecular-response is consistent with the primary endpoint. VAF is detected in bone-marrow samples via next-generation sequencing (NGS). |
| Secondary | Relapse-Free Survival (RFS) Rate at 6 Months | up to 6 months | |
| Secondary | Relapse-Free Survival (RFS) Rate at 12 Months | up to 12 months | Proportion of patients without relapse |
| Secondary | Overall Survival (OS) Rate | Up to 12 months | Proportion of patients alive |
| Secondary | Cumulative Incidence of Relapse (CIR) | Up to 12 months | Cumulative rate of relapse events |
| Secondary | Cumulative Remission-Phase Mortality Rate | Up to 12 months | Cumulative rate of deaths during remission |
| Secondary | Rate of Overall Response of DNMT3A R882 Mutation VAF at 3 Months | up to 3 months | |
| Secondary | Rate of Overall Response of DNMT3A R882 Mutation VAF at 6 Months | up to 6 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07188740
GET https://conductscience.org/api/trials/v1/NCT07188740/registered